Application Data
(This assay recognizes both recombinant and natural Human UPAR. The factors listed below were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed. Preparations of the following factors at 5ng/mL in a mid-range recombinant human UPAR control were assayed for interference. No significant interference was observed.)
Human PLAUR/CD87 ELISA Kit | PLAUR/CD87 elisa kit
Human PLAUR/CD87 ELISA Kit
Reactivity
Human
Synonyms
PLAUR/CD87; N/A; Human PLAUR/CD87 ELISA Kit; Chorionic Gonadotropin/CGA ELISA Kit, Huma; plasminogen activator, urokinase receptor; CD87 ELISA Kit, Human; U-PAR ELISA Kit, Human; UPAR ELISA Kit, Human; URKR ELISA Kit, Human; PLAUR/CD87 elisa kit
Reactivity
Human
Specificity
For the quantitative determination of Human PLAUR/CD87 concentration in serum.
Assay Type
Solid Phase Sandwich ELISA (quantitative)
Sample Types
Serum
Detection Range
4.69-300pg/mL
Sensitivity
2.32pg/mL
Conjugation
HRP
Materials Provided
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
Application Data
(This assay recognizes both recombinant and natural Human UPAR. The factors listed below were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed. Preparations of the following factors at 5ng/mL in a mid-range recombinant human UPAR control were assayed for interference. No significant interference was observed.)
Application Data
(This assay recognizes both recombinant and natural Human UPAR. The factors listed below were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed. Preparations of the following factors at 5ng/mL in a mid-range recombinant human UPAR control were assayed for interference. No significant interference was observed.)
Standard Curve (Sample)
(This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.)
Standard Curve (Sample)
(This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.)
Related Product Information for PLAUR/CD87 elisa kit
This uPAR/PLAUR ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human uPAR/PLAUR protein in Serum. It contains recombinant Human uPAR/PLAUR, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
Background: Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor-uPAR) expression has a potential role in the test or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
Background: Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor-uPAR) expression has a potential role in the test or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
References
Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
Similar Products
Product Notes
The Human PLAUR/CD87 (Catalog #AAA258405) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA258405 ELISA Kit recognizes Human PLAUR/CD87. It is sometimes possible for the material contained within the vial of "PLAUR/CD87, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.